Saturday 17 October 2026
Export RAPP’s income statement to Excel — free account
Rapport Therapeutics, Inc.
RAPP Healthcare Biotechnology
In the quarter to June 2026, EPS fell 58.7% and free cash flow fell 64.8%, each against the same quarter a year earlier.
27.57
2.00
−6.76%
Follow RAPP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | 0.00 | — |
P/S ratio |
— | — | 0.00 | — | |
P/FCF ratio |
— | — | 0.00 | — | |
P/Operating CF |
— | — | (113.16) | — | |
P/B ratio |
— | — | 3.13 | — | |
Price to Tangible BV |
— | — | 3.13 | — | |
EV/Sales |
— | — | 0.00 | — | |
EV/EBITDA |
— | — | 0.00 | — | |
EV/Operating CF |
— | — | (12.47) | — | |
EV/FCF |
— | — | (12.40) | — | |
Quick Ratio |
35.84 | 25.76 | 26.65 | 15.36 | |
Current Ratio |
36.37 | 26.17 | 27.08 | 15.72 | |
Net Debt/EBITDA |
17.38 | 12.48 | 19.58 | 7.24 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.65 | 0.73 | 0.66 | 0.73 | |
Capex/Depreciation |
(0.29) | 0.21 | 0.63 | 0.21 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 163.58% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 57.50% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 34.82% | 0.00% | |
Graham Net Nets |
— | — | 0.31 | — | |
Graham Number |
— | — | 0.00 | — | |
Earnings Yield |
— | — | (8.31%) | — | |
Free Cash Flow Yield |
— | — | (5.46%) | — | |
Revenue per Share |
0.00 | 0.00 | 0.42 | 0.00 | |
Operating CF per Share |
(0.46) | (0.63) | (0.28) | (0.87) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.46) | (0.64) | (0.28) | (0.87) | |
Cash per Share |
13.53 | 12.60 | 10.10 | 9.19 | |
Shareholders Equity per Share |
13.49 | 12.45 | 9.98 | 8.91 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
13.49 | 12.45 | 9.98 | 8.91 | |
Free Cash Flow |
(17.60) | (24.87) | (13.15) | (41.34) | |
Working Capital |
506.34 | 479.51 | 466.80 | 418.43 | |
Capital Expenditures |
(0.13) | (0.17) | (0.09) | 0.12 | |
Net Current Asset Value |
496.95 | 470.78 | 458.61 | 410.80 | |
EV/EBIT |
— | — | 0.00 | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | — | |
| Other line items | |||||
Average Payables |
2.28 | 3.07 | 4.35 | 2.99 | |
Average Assets |
433.23 | 413.68 | 399.83 | 372.24 | |
Average Common Equity |
417.37 | 395.04 | 378.67 | 343.22 |
Columns are period end dates